2022年10月7日 · HM3 is the most common durable LVAD currently being manufactured and implanted in the United States. While there are still some axial-flow HeartMate 2 and centrifugal-flow. HeartWare LVADs in circulation, recent studies showed improved outcomes with HM3 when compared to these devices prompting a transition to HM3. [PMID: 34980564]

Learn more about the HeartMate 3 LVAD procedure with the following procedure information and videos for healthcare professionals.

The HeartMate 3™ LVAD, a mechanical circulatory support pump with Full MagLev™ Flow Technology has significantly advanced the field of LVAD therapy, setting the standard with innovation and outstanding clinical outcomes that make a …

2024年4月9日 · DOT-HM3 indicates Direct Oral Anticoagulant Therapy With the HeartMate 3 LVAD; GI, gastrointestinal; and HTx, heart transplant. The DOT-HM3 study demonstrated the feasibility of using a DOAC (with or without aspirin) in patients chronically supported with HM3 LVAD for a duration of 6 months.

Learn about the benefits of the HeartMate 3 LVAD for your heart failure patients. System Set-Up. This video describes how to inspect and prepare each of the components used in the implant procedure of the HeartMate 3 LVAD. Setting up the System Controller. This video shows how to set up the system controller for the HeartMate 3 LVAD.

2020年4月1日 · In the primary end point analysis, HM3 use was superior to HMII use in patients in the BTT/BTC group (76.8% vs 67.3% for survival free of disabling stroke and reoperation; hazard ratio, 0.62 [95% CI, 0.40-0.94]; log-rank P = .02) and patients in the DT group (73.2% vs 58.7%; hazard ratio, 0.61 [95% CI, 0.46-0.81]; log-rank P < .001).

2022年3月22日 · Since U.S. FDA approval of the HM3 for DT in October 2018, this device has accounted for almost 80% of durable implants in the United States. 5 Moreover, Medtronic ceased sales of the HVAD in June 2021, primarily due to a higher incidence of adverse neurologic events and pump thrombosis. 11 Thus, until another commercial LVAD is approved, the ...

2018年5月2日 · In this article, the surgical implantation technique for the latest-generation of intrapericardial, fully magnetically levitated centrifugal continuous-flow LVADs is described in detail for the HeartMate 3 system. Each step is illustrated by several sketches and surgically important steps are discussed.

Findings from the clinical effectiveness review demonstrate that LVADs have significantly improved over time and the currently available HM3 LVAD is considered clinically effective in patients with end-stage HF ineligible for transplant, with the available evidence suggesting it may offer survival of over 75% at 2 years of follow-up with reduced...

The HeartMate 3 (HM3) (Abbott Cardiac Arrhythmias and Heart Failure, Plymouth, MN) is a new generation centrifugal ventricular assist device (VAD) characterized by a fully levitated rotor that lacks mechanical bearings. The HM3 design has short and wide inflow that decreases shear stress and provides a reliable blood flow pattern supply (Figure 1).